Related Experiment Video
Updated: Jul 8, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Multi-proteomic Biomarker Risk Scores for Predicting Risk and Guiding Therapy in Patients with Coronary Artery
Matthew E Gold1, Edward Woods2, Darlington Pobee2
1Division of Cardiology, Department of Medicine, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, 1760 Haygood Dr NE, Atlanta, GA, USA.
Insights
Biomarker risk scores (BRS) identify patients with coronary artery disease (CAD) at high risk for adverse events. These scores help target therapies and predict outcomes, improving patient care.
Area of Science:
- Cardiovascular Medicine
- Biomarker Discovery
- Translational Research
Background:
- Established coronary artery disease (CAD) patients face significant residual risk despite current treatments.
- Identifying individuals at highest risk is crucial for effective intervention.
Purpose of the Study:
- To evaluate the utility of multi-biomarker risk scores (BRS) in stratifying residual risk in patients with established CAD.
- To determine if BRS can identify patients who may benefit from intensified therapies.
Main Methods:
- Analysis of circulating biomarkers reflecting atherosclerosis and myocardial dysfunction pathways.
- Development and application of multi-protein biomarker risk scores (BRS).
Main Results:
- Multi-protein BRS accurately stratify patients with established CAD beyond traditional risk factors.
- Elevated BRS identify individuals at greater residual risk for adverse events.
- Improvements in BRS correlate with parallel improvements in clinical outcomes.
Conclusions:
- Biomarker risk scores offer a valuable tool for identifying high-residual-risk CAD patients.
- BRS can guide therapeutic intensification and monitor treatment effectiveness.
- These scores have potential clinical utility for personalized risk management in CAD.
Purpose Of Review:
Patients with established coronary artery disease (CAD) are at high residual risk for adverse events, despite guideline-based treatments. Herein, we aimed to determine whether risk scores based on multiple circulating biomarkers that represent activation of various pathophysiologically important pathways involved in atherosclerosis and myocardial dysfunction help identify those at greatest residual risk.
Recent Findings:
Numerous circulating proteins, representing dysregulation of the pathways involved in the development and stability of coronary and myocardial diseases, have been identified. When aggregated together, biomarker risk scores (BRS) more accurately stratify patients with established CAD that may help target interventions in those individuals who are at elevated risk. Moreover, intensification of guideline-based therapies has been associated with parallel improvements in both BRS and outcomes, indicating that these risk scores may be employed clinically to target therapy. Multi-protein BRS are predictive of risk, independent of, and in addition to traditional risk factor assessments in patients with CAD. Those with elevated risk may benefit from optimization of therapies, and improvements in the BRS will identify those with improved outcomes.
More Related Videos
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...